The underlying clotting factor deficiency in hemophilia does not change as you age. Your factor levels are set by your genetics and stay essentially the same throughout your life. But the cumulative toll of living with hemophilia, from joint damage to bone loss to complications from past treatments, does increase over time. So while the disease itself doesn’t technically worsen, its impact on your body almost certainly does.
Your Factor Levels Stay the Same
Hemophilia severity is determined by the specific genetic mutation you carry, and it remains stable within individuals and families. If you were diagnosed with moderate hemophilia as a child, you’ll still have moderate hemophilia at 60. Your body doesn’t gradually lose the ability to produce clotting factor beyond what the genetic defect already dictates.
There is one rare exception. A subtype called hemophilia B Leyden starts out as severe or moderate in childhood but improves dramatically at puberty. Rising growth hormone levels appear to normalize factor IX production, essentially resolving the condition. This has only been identified in hemophilia B and has no equivalent in hemophilia A.
Joint Damage Builds Over Decades
The most visible way hemophilia “worsens” with age is through cumulative joint damage. Repeated bleeds into the same joint, especially the knees, ankles, and elbows, gradually destroy the cartilage and cause chronic arthritis known as hemophilic arthropathy. In a study of adults with severe or moderate hemophilia, 87% showed at least early-stage joint damage, and physical function scores correlated strongly with age. The older the patient, the worse the joint scores, even when accounting for treatment. Mild hemophilia showed no such correlation.
This progressive joint breakdown has a cascade effect. Damaged joints limit mobility, which leads to a more sedentary lifestyle, which accelerates other problems like bone loss and weight gain. In one Brazilian cohort, nearly 65% of people with severe or moderate hemophilia were receiving disability benefits due to hemophilia complications, at an average age of just 35.
Bone Loss Starts Earlier Than Expected
People with hemophilia develop osteoporosis at younger ages than the general population. One study found that 27% of hemophilia patients had osteoporosis and 43% had low bone mineral density overall. In another cohort, half of all patients had below-normal bone density, and the average age of those with bone loss (41 years) was significantly younger than those with normal bones (34 years).
Several factors drive this. Repeated joint bleeds during childhood interfere with building peak bone mass. Reduced physical activity and limited weight-bearing exercise compound the problem. Infections with hepatitis C or HIV, which are common in people treated with blood products before modern screening, further weaken bones. Animal research has also shown that the clotting factor deficiency itself may directly reduce bone density, independent of joint bleeds or activity level. The practical result is a higher risk of fractures, especially as damaged joints already increase the likelihood of falls.
Complications From Past Treatments
Many people with hemophilia who are now middle-aged or older were exposed to contaminated blood products before screening became standard. CDC data from over 2,200 men with hemophilia aged 45 and older found that nearly 3 in 4 had a history of hepatitis C infection, and about 1 in 4 had contracted HIV. Those with a history of either infection had significantly higher rates of chronic kidney disease, liver cancer, anxiety, and depression compared to men with hemophilia who avoided infection.
Chronic kidney disease in particular creates a dangerous feedback loop: it drives up blood pressure, which is already more common in older people with hemophilia than in the general population. High blood pressure is a risk factor for both heart disease and cerebral hemorrhage, the latter being especially dangerous when your blood doesn’t clot properly.
Heart Disease Creates a Treatment Paradox
As people with hemophilia live longer, they develop the same cardiovascular risks as everyone else. High cholesterol, diabetes, smoking, and hypertension can overcome the bleeding disorder and lead to heart attacks and strokes. CDC data actually found that men with hemophilia had lower rates of coronary artery disease, stroke, and heart attack than the general population, but the conditions still occur and present unique challenges.
The core problem is a treatment conflict. Standard heart disease management relies heavily on blood thinners, which are obviously risky for someone who already can’t clot well. Clot-dissolving drugs used during heart attacks carry an unacceptable hemorrhage risk in hemophilia and are generally replaced with procedures like angioplasty. When heart valve surgery is needed, doctors prefer biological valves over mechanical ones because mechanical valves require lifelong anticoagulation. Every cardiovascular decision involves balancing the bleeding risk against the clotting risk, and this balancing act gets more complex with age.
Mental Health and Quality of Life
The CDC study found that men with hemophilia had higher rates of anxiety, depression, and obesity compared to the general male population. This held true even without accounting for infection history, though HIV and hepatitis C made both conditions more prevalent. Living with chronic pain from damaged joints, limited mobility, and the ongoing management burden of a lifelong bleeding disorder takes a psychological toll that compounds over the years.
Life Expectancy Has Improved Dramatically
Modern treatment has transformed hemophilia from a condition that often killed in early adulthood to one compatible with a long life. Data from the Netherlands shows that median life expectancy for people with hemophilia rose from 66 years in the 1973-1986 period to 77 years in 2001-2018. The general male population’s life expectancy rose from 79 to 83 over the same period, meaning the gap narrowed from 13 years to 6.
Severity still matters. People with moderate hemophilia had a median life expectancy of 80 years and those with mild hemophilia reached 79, both essentially matching the general population. Severe hemophilia carried a median life expectancy of 73 years. The fact that so many more people with hemophilia now reach their 60s, 70s, and beyond is precisely why age-related complications have become such an important issue. These are problems earlier generations simply didn’t live long enough to face.
The Inhibitor Question
One concern as people with hemophilia age is whether they might develop inhibitors, antibodies that attack replacement clotting factor and make treatment ineffective. A large European surveillance study covering nearly 69,000 treatment years found the overall inhibitor rate in previously treated patients with severe hemophilia A was about 1 per 1,000 treatment years, and the rate did not increase after age 59. An older UK registry had suggested a second peak in inhibitor development among patients over 59, but the larger European data did not confirm this pattern. Inhibitor development remains primarily a risk during early treatment in childhood, not something that escalates with aging.